Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________

FORM 10-Q

________________________________

CHECK ONE:



ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended: March 31, 2019



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file No.: 1-12996

________________________________

Diversicare Healthcare Services, Inc.

(exact name of registrant as specified in its charter)

________________________________



Delaware		62-1559667
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

1621 Galleria Boulevard, Brentwood, TN 37027

(Address of principal executive offices) (Zip Code)

(615) 771-7575

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨(do not check if a smaller reporting company)	Smaller reporting company	ý
		Emerging growth company	¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.			¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No ý

Securities registered pursuant to Section 12(b) of the Act:



Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	DVCR	The Nasdaq Capital Market

6,682,260

(Outstanding shares of the issuer’s common stock as of April 29, 2019)

Part I. FINANCIAL INFORMATION

ITEM 1 – FINANCIAL STATEMENTS

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

INTERIM CONSOLIDATED BALANCE SHEETS

(in thousands)



	March 31, 2019			December 31, 2018
	(Unaudited)
CURRENT ASSETS:
Cash and cash equivalents	$	2,465		$	2,685
Receivables	63,864			66,257
Self-insurance receivables	1,775			4,475
Other receivables	1,169			1,191
Prepaid expenses and other current assets	4,489			4,728
Income tax refundable	553			1,115
Current assets of discontinued operations	—			86
Total current assets	74,315			80,537
PROPERTY AND EQUIPMENT, at cost	139,954			138,460
Less accumulated depreciation and amortization	(87,666		)	(85,361		)
Property and equipment, net	52,288			53,099
OTHER ASSETS:
Deferred income taxes, net	17,022			15,851
Deferred leasehold costs	—			206
Operating lease assets	377,799			—
Acquired leasehold interest, net	6,136			6,307
Other noncurrent assets	3,309			3,244
Total other assets	404,266			25,608
	$	530,869		$	159,244

The accompanying notes are an integral part of these interim consolidated financial statements.

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

INTERIM CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

(continued)



	March 31, 2019			December 31, 2018
	(Unaudited)
CURRENT LIABILITIES:
Current portion of long-term debt and finance lease obligations, net	$	10,390		$	12,449
Trade accounts payable	15,137			15,659
Current liabilities of discontinued operations	—			86
Current portion of operating lease liabilities	22,205			—
Accrued expenses:
Payroll and employee benefits	17,643			19,471
Self-insurance reserves, current portion	10,881			13,158
Provider taxes	2,381			2,394
Other current liabilities	6,697			7,128
Total current liabilities	85,334			70,345
NONCURRENT LIABILITIES:
Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	64,069			60,984
Operating lease liabilities, less current portion	362,094			—
Self-insurance reserves, noncurrent portion	15,875			16,057
Litigation contingency	6,400			6,400
Other noncurrent liabilities	1,522			6,656
Total noncurrent liabilities	449,960			90,097
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ DEFICIT:
Common stock, authorized 20,000 shares, $.01 par value, 6,914 and 6,751 shares issued, and 6,682 and 6,519 shares outstanding, respectively	69			68
Treasury stock at cost, 232 shares of common stock	(2,500		)	(2,500		)
Paid-in capital	23,594			23,413
Accumulated deficit	(26,362		)	(23,016		)
Accumulated other comprehensive income	774			837
Total shareholders’ deficit	(4,425		)	(1,198		)
	$	530,869		$	159,244

The accompanying notes are an integral part of these interim consolidated financial statements.

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts, unaudited)



	Three Months Ended March 31,
	2019			2018
PATIENT REVENUES, net	$	134,353		$	141,285
EXPENSES:
Operating	108,113			112,278
Lease and rent expense	15,804			13,713
Professional liability	3,421			2,775
General and administrative	7,513			8,139
Depreciation and amortization	2,494			2,881
Total expenses	137,345			139,786
OPERATING INCOME (LOSS)	(2,992		)	1,499
OTHER INCOME (EXPENSE):
Other income	160			51
Interest expense, net	(1,460		)	(1,669		)
Total other expense	(1,300		)	(1,618		)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(4,292		)	(119		)
BENEFIT FOR INCOME TAXES	955			38
LOSS FROM CONTINUING OPERATIONS	(3,337		)	(81		)
LOSS FROM DISCONTINUED OPERATIONS:
Operating loss, net of tax expense of $0 and $11, respectively	(9		)	(22		)
NET LOSS	$	(3,346	)	$	(103	)
NET LOSS PER COMMON SHARE:
Per common share – basic
Continuing operations	$	(0.52	)	$	(0.01	)
Discontinued operations	—			—
	$	(0.52	)	$	(0.01	)
Per common share – diluted
Continuing operations	$	(0.52	)	$	(0.01	)
Discontinued operations	—			—
	$	(0.52	)	$	(0.01	)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK	$	—		$	0.055
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	6,424			6,314
Diluted	6,424			6,314

The accompanying notes are an integral part of these interim consolidated financial statements.

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands and unaudited)



	Three Months Ended March 31,
	2019			2018
NET LOSS	$	(3,346	)	$	(103	)
OTHER COMPREHENSIVE INCOME:
Change in fair value of cash flow hedge, net of tax	(63		)	322
Less: reclassification adjustment for amounts recognized in net loss	—			(114		)
Total other comprehensive income (loss)	(63		)	208
COMPREHENSIVE INCOME (LOSS)	$	(3,409	)	$	105

The accompanying notes are an integral part of these interim consolidated financial statements.

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)

(in thousands and unaudited)



Three Months Ended March 31, 2019
	Common Stock			Treasury Stock				Paid-in Capital		Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)			Total Shareholders' Deficit
	Shares Issued	Amount		Shares	Amount			Paid-in Capital		Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)			Total Shareholders' Deficit

BALANCE, DECEMBER 31, 2018	6,751	$	68	232	$	(2,500	)	$	23,413	$	(23,016	)	$	837		$	(1,198	)
Net loss	—	—		—	—			—		(3,346		)	—			(3,346		)
Issuance/redemption of equity grants, net	163	1		—	—			41		—			—			42
Interest rate cash flow hedge	—	—		—	—			—		—			(63		)	(63		)
Stock-based compensation	—	—		—	—			140		—			—			140

BALANCE, MARCH 31, 2019	6,914	$	69	232	$	(2,500	)	$	23,594	$	(26,362	)	$	774		$	(4,425	)



Three Months Ended March 31, 2018
	Common Stock			Treasury Stock				Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)		Total Shareholders' Equity
	Shares Issued	Amount		Shares	Amount			Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)		Total Shareholders' Equity

BALANCE, DECEMBER 31, 2017	6,687	$	67	232	$	(2,500	)	$	22,720		$	(14,534	)	$	709	$	6,462
Net loss	—	—		—	—			—			(103		)	—		(103		)
Common stock dividends declared	—	—		—	—			13			(363		)	—		(350		)
Issuance/redemption of equity grants, net	86	1		—	—			(79		)	—			—		(78		)
Interest rate cash flow hedge	—	—		—	—			—			—			208		208
Stock-based compensation	—	—		—	—			236			—			—		236

BALANCE, MARCH 31, 2018	6,773	$	68	232	$	(2,500	)	$	22,890		$	(15,000	)	$	917	$	6,375

The accompanying notes are an integral part of these interim consolidated financial statements.

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands and unaudited)



	Three Months Ended March 31,
	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,346	)	$	(103	)
Discontinued operations	(9		)	(22		)
Loss from continuing operations	(3,337		)	(81		)
Adjustments to reconcile loss from continuing operations to net cash provided by operating activities:
Depreciation and amortization	2,494			2,881
Deferred income tax provision (benefit)	(1,090		)	—
Provision for self-insured professional liability, net of cash payments	1,444			956
Stock-based and deferred compensation	156			284
Provision (benefit) for leases in excess of cash payments	1,280			(453		)
Other	335			140
Changes in assets and liabilities affecting operating activities:
Receivables, net	5,315			2,017
Prepaid expenses and other assets	(2,966		)	(439		)
Trade accounts payable and accrued expenses	(3,269		)	(86		)
Net cash provided by continuing operations	362			5,219
Discontinued operations	(9		)	(474		)
Net cash provided by operating activities	353			4,745
NET CASH FLOWS USED IN INVESTING ACTIVITIES:
Purchases of property and equipment	(1,512		)	(2,012		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt and finance lease obligations	(1,112		)	(4,762		)
Proceeds from issuance of debt	2,049			5,651
Financing costs	(40		)	(132		)
Issuance and redemption of employee equity awards	42			(78		)
Payment of common stock dividends	—			(350		)
Payment for preferred stock restructuring	—			(168		)
Net cash provided by continuing operations	939			161
Discontinued operations	—			—
Net cash provided by financing activities	$	939		$	161

The accompanying notes are an integral part of these interim consolidated financial statements.

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands and unaudited)

(continued)



	Three Months Ended March 31,
	2019			2018
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	$	(220	)	$	2,894
CASH AND CASH EQUIVALENTS, beginning of period	2,685			3,524
CASH AND CASH EQUIVALENTS, end of period	$	2,465		$	6,418
SUPPLEMENTAL INFORMATION:
Cash payments of interest	$	1,289		$	1,432
Cash receipts of income taxes	$	(426	)	$	(16	)
SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Acquisition of equipment through finance leases	$	49		$	—
Acquisition of operating leases through adoption of ASC 842	$	389,403		$	—

The accompanying notes are an integral part of these interim consolidated financial statements.

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2019 AND 2018

(Dollars and shares in thousands, except per share data)

(Unaudited)


1.	BUSINESS

Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.

As of March 31, 2019, the Company’s continuing operations consist of 72 nursing centers with 8,214 licensed nursing beds. The Company owns 15 and leases 57 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 429 licensed assisted and residential living beds.


2.	CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS

The interim consolidated financial statements for the three month periods ended March 31, 2019 and 2018, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2019, and the results of operations for the three month periods ended March 31, 2019 and 2018, changes in shareholders' equity (deficit) for the three month periods ended March 31, 2019 and 2018, and cash flows for the three month periods ended March 31, 2019 and 2018. The Company’s balance sheet information at December 31, 2018, was derived from its audited consolidated financial statements as of December 31, 2018.

Effective January 1, 2019, we adopted the requirements of Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), as discussed in Notes 3 and 6 to the interim consolidated financial statements. Effective January 1, 2018, we adopted the requirements of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standards.

The results of operations for the periods ended March 31, 2019 and 2018 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.


3.	RECENT ACCOUNTING GUIDANCE

Recent Accounting Standards Adopted by the Company

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short-term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make (and the Company chose to utilize) an accounting policy election by asset class not to recognize ROU assets and lease liabilities, which would generally result in lease expense for these short term leases being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company elected to use the optional expedient to reflect adoption in the period of adoption (January 1, 2019) rather than the earliest period presented. The Company also elected the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The adoption of the new standard resulted in the recording of net lease assets and lease liabilities of $384,187 and

$389,403, respectively, as of January 1, 2019. The standard did not materially impact our consolidated net earnings and had no impact on cash flows. See Note 6, "Leases" for a discussion regarding leases under the new standard.

In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures.

In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures.

In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvement to Nonemployee Share-Based Payment Accounting, which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. The standard is effective for fiscal years beginning after December 15, 2018. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures.

In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. The new guidance is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The adoption of ASC 606 represents a change in accounting principle that more closely aligns revenue recognition with the delivery of the Company's services. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The new guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or

conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.

Accounting Standards Recently Issued But Not Yet Adopted by the Company

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements of fair value measurements under Topic 820. The standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.

In October 2018, the FASB issued ASU No. 2018-16, Derivatives and Hedging (Topic 805): Inclusion of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. The ASU amends ASC 815 to add the OIS rate based on the SOFR as a fifth US benchmark interest rate. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.

4. REVENUE RECOGNITION

On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The adoption of ASC 606 represents a change in accounting principle that more closely aligns revenue recognition with the delivery of the Company's services. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:

Step 1: Identify the contract with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.

The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).

In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration

better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.

The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.

The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

Disaggregation of Revenue and Accounts Receivable

The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):



	Three Months Ended March 31,
	2019				2018
Medicaid	$	63,531	47.3	%	$	63,886	45.2	%
Medicare	25,055		18.6	%	29,751		21.1	%
Managed Care	14,175		10.6	%	14,212		10.1	%
Private Pay and other	31,592		23.5	%	33,436		23.6	%
Total	$	134,353	100.0	%	$	141,285	100.0	%

Accounts receivable as of March 31, 2019 and December 31, 2018 are summarized in the following table:



	March 31,		December 31,
	2019		2018
Medicaid	$	25,971	$	27,532
Medicare	13,249		15,706
Managed Care	9,083		8,126
Private Pay and other	15,561		14,893
Total accounts receivable	$	63,864	$	66,257


5.	LONG-TERM DEBT AND INTEREST RATE SWAP

The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five-year term of the agreements.

Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five-year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000. The Amended Mortgage Loan balance was $58,150 as of March 31, 2019, consisting of $51,250 on the term

loan facility with an interest rate of 6.50% and $6,900 on the acquisition loan facility with an interest rate of 7.25%. The Amended Mortgage Loan is secured by fifteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.

Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $42,250.

On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Revolving Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000.

Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500.

Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.

Effective December 1, 2018, the Company entered into the Sixth Amendment ("Sixth Revolver Amendment") to amend the Amended Revolver. The Sixth Amendment decreased the Amended Revolver capacity from $52,250 to $42,250. The Company also applied $4,947 of net proceeds from the sale of the Kentucky centers to the outstanding borrowings under the Amended Revolver.

Effective December 1, 2018, the Company executed a Fourth Amendment (the "Fourth Term Amendment") to amend the Amended Mortgage Loan. The Company applied $11,100 and $2,100 of net proceeds from the sale of the Kentucky centers to the Term Loan and Acquisition Loan, respectively. Additionally, we amended the Acquisition Loan availability to include a reserve of $2,100, and therefore, our borrowing capacity is $10,400. For further discussion of the sale of the Kentucky centers, refer to Note 10, "Business Development and Other Significant Transactions."

As of March 31, 2019, the Company had $16,500 borrowings outstanding under the Amended Revolver compared to $15,000 outstanding as of December 31, 2018. The interest rate related to the Amended Revolver was 6.50% as of March 31, 2019. The outstanding borrowings on the revolver were used primarily for temporary working capital requirements. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has four letters of credit with a total value of $13,594 outstanding as of March 31, 2019. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $36,679 the balance available for borrowing under the Amended Revolver was $6,585 at March 31, 2019.

The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at March 31, 2019.

Interest Rate Swap Transaction

As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $27,450 as of March 31, 2019. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.

The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at March 31, 2019, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of $230 at March 31, 2019. The fair value of the interest rate swap is included in “other noncurrent assets” on the Company’s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at March 31, 2019 is $161 net of the income tax provision of $69. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future

LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.

6. LEASES

The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have remaining lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.



Leases
	Classification	March 31, 2019
Assets
Operating lease assets	Operating lease assets	377,799
Finance lease assets	Property and equipment, net^(a)	1,045
Total leased assets		378,844

Liabilities
Current
Operating	Current portion of operating lease liabilities	22,205
Finance	Current portion of long-term debt and finance lease obligations, net	383
Noncurrent
Operating	Operating lease liabilities	362,094
Finance	Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	466
Total lease liabilities		385,148

^(a)Finance lease assets are recorded net of accumulated amortization of 1,283 as of March 31, 2019.



Lease Cost		Three Months Ended
	Classification	March 31, 2019
Operating lease cost ^(a)	Lease and rent expense	15,804
Finance lease cost:
Amortization of finance lease assets	Depreciation and amortization	67
Interest on finance lease liabilities	Interest expense, net	11
Short term lease cost	Operating expense	141
Net lease cost		16,023

^(a)Includes variable lease costs, which are immaterial



Three Months Ended March 31, 2019
Maturity of Lease Liabilities	Operating Leases ^(a)		Finance Leases ^(a)		Total

2019	58,586		429		59,015
2020	59,666		212		59,878
2021	60,856		197		61,053
2022	62,075		100		62,175
2023	63,211		—		63,211
After 2023	305,640		—		305,640
Total lease payments	610,034		938		610,972
Less: Interest	(225,735	)	(89	)	(225,824	)
Present value of lease liabilities	384,299		849		385,148

^(a) Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.

The Company's future minimum lease commitments as of December 31, 2018, under Accounting Standards Codification Topic 840, predecessor to Topic 842, are as follows:



Twelve Months Ended December 31, 2018
Maturity of Lease Liabilities	Operating Leases ^(a)	Finance Leases ^(a)	Total

2018	58,291	454	58,745
2019	59,391	174	59,565
2020	60,575	173	60,748
2021	61,808	127	61,935
2022	63,065	—	63,065
After 2022	321,797	—	321,797
Total lease payments	624,927	928	625,855

^(a) Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.

The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term.



Lease Term and Discount Rate		March 31, 2019

Weighted-average remaining lease term (years)
Operating leases		9.77
Finance leases		2.62
Weighted-average discount rate
Operating leases		9.9%
Finance leases		6.60%



Other Information	Three Months Ended
	March 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	14,516
Operating cash flows from finance leases	$	11
Financing cash flows from finance leases	$	132
Acquisition of operating leases through adoption of ASC 842	$	389,403

7. COMMITMENTS AND CONTINGENCIES

Professional Liability and Other Liability Insurance

The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.

Reserve for Estimated Self-Insured Professional Liability Claims

Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,625 and $27,201 as of March 31, 2019 and December 31, 2018, respectively. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.

The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.

On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.

As of March 31, 2019, the Company is engaged in 78 professional liability lawsuits. Twenty-seven lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $1,906 and $1,093 for the three months ended March 31, 2019 and 2018, respectively.

The Company follows the accounting guidance in ASC Topic 954 that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" and "Other Noncurrent Assets" on the Consolidated Balance Sheet. As of March 31, 2019 there are estimated insurance recovery receivables of $2,125. There were no estimated insurance recovery receivables as of March 31, 2018.

Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.

Civil Investigative Demand ("CID")

In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").

In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.

Discussions continue with the DOJ regarding settlement of this investigation. The Company denies any wrong doing and is prepared to vigorously defend its actions if a settlement is not reached. The Company accrued $6,400 as a contingent liability in connection with this matter during the three months ended September 30, 2018, but the Company cannot predict whether a settlement can be achieved, the outcome of the litigation if there is no settlement or the length of time necessary to conclude this matter. Accordingly, the contingent liability has been classified as a noncurrent liability in the accompanying interim consolidated balance sheets. The Company’s ultimate ability to settle this investigation will depend on several factors, including whether the amount and terms of an acceptable settlement can be reached with the DOJ, the Company’s assessment of the risks of litigating this case and the effect of protracted litigation or settlement terms on the Company’s business plans. Because the outcome of this investigation and related settlement discussions remain uncertain, there is a reasonable possibility that the amount ultimately incurred in connection with the resolution of this matter could differ materially from the current accrual, as the Company cannot, at this time, estimate the possible range of loss that may result from either a settlement or litigation of this matter. The ultimate outcome of this litigation could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement.

In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to the practices of some of its employees with respect to PAEs and PASRRs, and the Company provided documents responsive to this subpoena and coordinated examinations of certain employees of the Company. The Company understands that this criminal investigation has been closed, subject to re-opening at the discretion of the government.

Other Insurance

With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. From the period from July 1, 2008 through March 31, 2019, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $688 and $618 at March 31, 2019 and December 31, 2018, respectively.. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,458 and $1,258 as of March 31, 2019 and December 31, 2018, respectively. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.

As of March 31, 2019, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims

at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,444 at March 31, 2019. The differences between actual settlements and reserves are included in expense in the period finalized.


8.	STOCK-BASED COMPENSATION

Overview of Plans

In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.

In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.

Equity Grants and Valuations

During the three months ended March 31, 2019 and 2018, the Compensation Committee of the Board of Directors approved grants totaling approximately 151 and 90 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest one-third on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. Our policy is to account for forfeitures of share-based compensation awards as they occur.

In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

Summarized activity of the equity compensation plans is presented below:



			Weighted
	Options/		Average
	SOSARs		Exercise Price
Outstanding, December 31, 2018	122		$	7.29
Granted	—		—
Exercised	(2	)	2.37
Expired or cancelled	(21	)	8.39
Outstanding, March 31, 2019	99		$	7.16

Exercisable, March 31, 2019	89		$	7.05



			Weighted
			Average
	Restricted		Grant Date
	Shares		Fair Value
Outstanding, December 31, 2018	120		$	8.77
Granted	151		3.93
Dividend Equivalents	—		—
Vested	(57	)	8.91
Cancelled	—
Outstanding, March 31, 2019	214		$	5.31

Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:



			Weighted
			Average
	Restricted		Grant Date
	Share Units		Fair Value
Outstanding, December 31, 2018	43		$	9.26
Granted	36		3.93
Dividend Equivalents	—		—
Vested	(30	)	9.76
Outstanding, March 31, 2019	49		$	5.05

The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2019:



	Weighted
	Average			Intrinsic			Intrinsic
Range of	Exercise		Grants	Value-Grants		Grants	Value-Grants
Exercise Prices	Prices		Outstanding	Outstanding		Exercisable	Exercisable
$8.14 to $10.21	$	8.83	45	$	—	35	$	—
$5.45 to $5.86	$	5.76	54	$	—	54	$	—
			99			89

Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $140 and $236 in the three month periods ended March 31, 2019 and 2018, respectively.


9.	EARNINGS PER COMMON SHARE

Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:



	Three Months Ended March 31,
	2019			2018
Net loss
Loss from continuing operations	$	(3,337	)	$	(81	)
Loss from discontinued operations, net of income taxes	(9		)	(22		)
Net loss	$	(3,346	)	$	(103	)



	Three Months Ended March 31,
	2019			2018
Net loss per common share:
Per common share – basic
Loss from continuing operations	$	(0.52	)	$	(0.01	)
Loss from discontinued operations	—			—
Net loss per common share – basic	$	(0.52	)	$	(0.01	)
Per common share – diluted
Loss from continuing operations	$	(0.52	)	$	(0.01	)
Loss from discontinued operations	—			—
Net loss per common share – diluted	$	(0.52	)	$	(0.01	)
Weighted Average Common Shares Outstanding:
Basic	6,424			6,314
Diluted	6,424			6,314

The effects of 99 and 30 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the three months ended March 31, 2019 and 2018, respectively, because these securities would have been anti-dilutive.


10.	BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS

2018 Assets Sold

On October 30, 2018 the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation, LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operation of Diversicare of Fulton, LLC, Diversicare of Clinton, LLC and Diversicare of Glasgow, LLC (the "Kentucky Properties"). On December 1, 2018, the Company completed the sale of the Kentucky Properties with the Buyers for a purchase price of $18,700. This transaction did not meet the accounting criteria to be reported as a discontinued operation. The carrying value of these centers' assets were $13,331, resulting in a gain of $4,825, with remaining proceeds for miscellaneous closing costs. The proceeds were used to relieve debt, which is required under the terms of the Company's Amended Mortgage Loan and Amended Revolver. Refer to Note 5, "Long-term Debt, Interest Rate Swap" for more information on this transaction.

2018 New Master Lease Agreement

On October 1, 2018, the Company entered into a New Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor") to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operated 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and Omega consolidates the leases for all 34 centers under one New Master Lease. The Lease has an initial term of twelve years with two 10-year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019.

11. SUBSEQUENT EVENTS

Effective April 1, 2019, the Company expanded it's participation in the Texas Quality Incentive Payment Program (“QIPP”) as administered by the Texas Health and Human Services Commission. Four skilled nursing centers previously operated by the Company entered into a transaction with a Texas medical district participating in the QIPP, providing for the transfer of the provider license from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district.

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Key Performance Metrics

Skilled Mix. Skilled mix represents the number of days our Medicare or Managed Care patients are receiving services at the skilled nursing facilities divided by the total number of days (less days from assisted living patients).

Average rate per day. Average rate per day is the revenue by payor source for a period at the skilled nursing facility divided by actual patient days for the revenue source for a given period.

Average daily skilled nursing census. Average daily skilled nursing census is the average number of patients who are receiving skilled nursing care.

Strategic Operating Initiatives

We identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives include: improving our facilities' quality metrics, improving skilled mix in our nursing centers, improving our average Medicare rate, implementing and maintaining Electronic Medical Records (“EMR”) to improve Medicaid capture, and completing strategic acquisitions and divestitures. We have experienced success in some of these initiatives and expect to continue to build on these improvements. In light of challenges facing the industry and the Company specifically, including the unresolved governmental investigation, we believe that now is not the time to attempt to engage in a company-wide strategic transaction.

Improving skilled mix and average Medicare rate:

One of our key performance indicators is skilled mix. Our strategic operating initiatives of improving our skilled mix and our average Medicare rate required investing in nursing and clinical care to treat more acute patients along with nursing center-based marketing representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract payor sources for patients covered by Medicare and Managed Care. The Company's skilled mix for the three months ended March 31, 2019 and 2018 was 14.9% and 16.1%, respectively.

Utilizing Electronic Medical Records to improve Medicaid acuity capture:

As another part of our strategic operating initiatives, all of our nursing centers utilize EMR to improve Medicaid acuity capture, primarily in our states where the Medicaid payments are acuity based. By using EMR, we have increased our average Medicaid rate despite rate cuts in certain acuity based states by accurate and timely capture of care delivery.

Completing strategic transactions:

Our strategic operating initiatives include a renewed focus on completing strategic acquisitions and divestitures. We continue to pursue and investigate opportunities to acquire or lease new centers, focusing primarily on opportunities within our existing geographic areas of operation. As part of our strategic efforts, we have also performed thorough analysis on our existing centers in order to determine whether continuing operations within certain markets or regions is in line with the short-term and long-term strategy of the business.

On October 30, 2018, the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, Diversicare of Clinton and Diversicare of Glasgow (the "Properties"). The purchase price of the Properties was $18.7 million and the sale was effective on December 1, 2018.

provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operates 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and Omega consolidates the leases for all 34 centers under one New Master Lease. The Lease has an initial term of twelve years with two 10 year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019.

On July 8, 2018, the Company entered into a membership interest purchase agreement with ALS Ontario Operating, Inc. to transfer all of the issued and outstanding membership units of Ontario Pointe, a stand-alone 50 bed assisted living facility. The termination of this lease was effective on October 1, 2018.

Basis of Financial Statements

Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our operating expenses include the costs, other than lease, professional liability, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.

Critical Accounting Policies and Judgments

A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments often involving estimates of the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income or loss to vary significantly from period to period. Our critical accounting policies are more fully described in our 2018 Annual Report on Form 10-K.

Revenue Sources

We classify our revenues from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and other. Medicaid revenues are composed of the traditional Medicaid program established to provide benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B of the Medicare program. Managed Care revenues include payments for patients who are insured by a third-party entity, typically called a Health Maintenance Organization, often referred to as an HMO plan, or are Medicare beneficiaries who assign their Medicare benefits to a Managed Care replacement plan often referred to as Medicare replacement products. The Private Pay and other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and other payors are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.

The following table sets forth net patient and resident revenues related to our continuing operations by primary payor source for the periods presented (dollar amounts in thousands). The balances below reflect the adoption of ASC 606 in January 2018. Refer to Note 4 "Revenue Recognition" to the interim consolidated financial statements.



	Three Months Ended March 31,
	2019				2018
Medicaid	$	63,531	47.3	%	$	63,886	45.2	%
Medicare	25,055		18.6	%	29,751		21.1	%
Managed Care	14,175		10.6	%	14,212		10.1	%
Private Pay and other	31,592		23.5	%	33,436		23.6	%
Total	$	134,353	100.0	%	$	141,285	100.0	%

The following table sets forth average daily skilled nursing census by primary payor source for our continuing operations for the periods presented:



	Three Months Ended March 31,
	2019			2018
Medicaid	4,424	68.7	%	4,589	67.9	%
Medicare	651	10.1	%	783	11.6	%
Managed Care	308	4.8	%	303	4.5	%
Private Pay and other	1,061	16.4	%	1,081	16.0	%
Total	6,444	100.0	%	6,756	100.0	%

Consistent with the nursing home industry in general, changes in the mix of a facility’s patient population among Medicaid, Medicare, Managed Care, and Private Pay and other can significantly affect the profitability of the facility’s operations.

Health Care Industry

The health care industry is subject to regulation by numerous federal, state, and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of patient care and Medicare and Medicaid fraud and abuse. Over the last several years, government activity has increased with respect to investigations and allegations concerning possible violations by health care providers of a number of statutes and regulations, including those regulating fraud and abuse, false claims, patient privacy and quality of care issues. Violations of these laws and regulations could result in exclusion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Compliance with such laws and regulations is subject to ongoing government review and interpretation, as well as regulatory actions in which government agencies seek to impose fines and penalties. The Company is involved in regulatory actions of this type from time to time.

In recent years, the U.S. Congress and some state legislatures have considered and enacted significant legislation concerning health care and health insurance. The most prominent of these efforts, the Affordable Care Act, affects how health care services are covered, delivered and reimbursed. As currently structured, the Affordable Care Act expands coverage through a combination of public program expansion and private sector reforms, provides for reduced growth in Medicare program spending, and promotes initiatives that tie reimbursement to quality and care coordination. Some of the provisions, such as the requirement that large employers provide health insurance benefits to full-time employees, have increased our operating expenses. The Affordable Care Act expands the role of home-based and community services, which may place downward pressure on our sustaining population of Medicaid patients. Reforms that we believe may have a material impact on the long-term care industry and on our business include, among others, possible modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. However, there is considerable uncertainty regarding the future of the Affordable Care Act. The Presidential administration and certain members of Congress have made and expressed their intent to repeal or make additional significant changes to the law, its implementation or its interpretation. For example, effective January 1, 2019, Congress eliminated the financial penalty associated with the individual mandate. Because the penalty associated with the individual mandate was eliminated, a federal judge in Texas ruled in December 2018 that the entire law was unconstitutional. However, the law remains in place pending appeal.

Skilled nursing centers are required to bill Medicare on a consolidated basis for certain items and services that they furnish to patients, regardless of the cost to deliver these services. This consolidated billing requirement essentially makes the skilled nursing center responsible for billing Medicare for all care services delivered to the patient during the length of stay. CMS has instituted a number of test programs designed to extend the reimbursement and financial responsibilities under consolidating billing beyond the traditional discharge date to include a broader set of bundled services. Such examples may include, but are not exclusive to, home health, durable medical equipment, home and community based services, and the cost of re-hospitalizations during a specified bundled period. Currently, these test programs for bundled reimbursement are confined to a small set of clinical conditions, but CMS has indicated that it is developing additional bundled payment models. This bundled form of reimbursement could be extended to a broader range of diagnosis related conditions in the future. The potential impact on skilled nursing center utilization and reimbursement is currently unknown.

On July 31, 2018, CMS issued a final rule outlining Medicare payment rates for skilled nursing facilities that became effective October 1, 2018. In addition, CMS updated the SNF market basket percentage to 2.4%, as required by the Bipartisan Budget Act of 2018. CMS finalized a payment system called the Patient-Driven Payment Model ("PDPM") to replace the Resource Utilization Group ("RUG-IV") model. The PDPM is an updated version of the 2017 Advanced Notice of Proposed Rulemaking Resident Classification System Version 1 ("RCS-1"). CMS notes RCS-1 was revised based on stakeholder input. The implementation date for the final system is October 1, 2019. CMS will use a budget neutrality factor to satisfy the requirement that PDPM be budget

neutral relative to RUG-IV. CMS stated that it intends for the new model not to change the aggregate amount of Medicare payments to SNFs, but to more accurately reflect resource utilization.

CMS publishes rankings based on performance scores on the Nursing Home Compare website, which is intended to assist the public in finding and comparing skilled care providers. The Nursing Home Compare website also publishes for each nursing home a rating between 1 and 5 stars as part of CMS’s Five-Star Quality Rating System. An overall star rating is determined based on three components (information from the last three years of health inspections, staffing information, and quality measures), each of which also has its own five-star rating. The ratings are based, in part, on the quality data nursing centers are required to report. For example, nursing centers must report the percentage of short-stay residents who are successfully discharged into the community and the percentage who had an outpatient emergency department visit.

In March 2019, CMS announced changes to the Five-Star Quality Rating System, effective April 2019. These changes include revisions to the inspection process, adjustment of staffing rating thresholds, including increased emphasis on registered nurse staffing, implementation of new quality measures, and changes in the scoring of various quality measures. CMS added two new quality measures: Long-stay emergency department transfers and long-stay hospitalizations. CMS also established separate quality ratings for short-stay and long-stay residents, and will now provide separate short-stay and long-stay ratings in addition to the overall quality measure rating. Ratings for the quality measures are based on 17 of the quality measures posted on the Nursing Home Compare website.

The impact of the most recent five star rating methodology is expected to be significant across the industry. The change in star ratings may be confusing to consumers. A center could lose stars as a result of these changes despite not changing its operations. These changes will also make comparisons to prior reporting periods not relevant. We remain diligent in continuing to provide outstanding patient care to achieve high rankings for our centers, as well as assuring that our rankings are correct and appropriately reflect our quality results. Our focus has been and continues to be on the delivery of quality care to our patients and residents.

Contractual Obligations and Commercial Commitments

We have certain contractual obligations of continuing operations as of March 31, 2019, summarized by the period in which payment is due, as follows (dollar amounts in thousands):



Contractual Obligations	Total		Less than 1 year		1 to 3 Years		3 to 5 Years		After 5 Years
Long-term debt obligations ⁽¹⁾	$	84,670	$	15,484	$	69,086	$	100	$	—
Settlement obligations ⁽²⁾	1,193		1,193		—		—		—
Operating leases ⁽³⁾	610,034		58,586		120,522		125,286		305,640
Required capital expenditures under operating leases ⁽⁴⁾	25,083		2,529		5,059		5,059		12,436
Total	$	720,980	$	77,792	$	194,667	$	130,445	$	318,076

(1)

Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our finance lease obligations. Our long-term debt obligations decreased $0.2 million between December 31, 2018 and March 31, 2019. See Note 5, "Long-Term Debt and Interest Rate Swap," to the interim consolidated financial statements included in this report for additional information.


(2)	Settlement obligations relate to professional liability cases that are expected to be paid within the next twelve months. The professional liabilities are included in our current portion of self-insurance reserves.


(3)	Represents minimum annual lease payments (exclusive of taxes, insurance, and maintenance costs) under our operating lease agreements, which does not include renewals. Our operating lease obligations decreased $14.9 million between December 31, 2018 and March 31, 2019. See Note 6, "Leases," to the interim consolidated financial statements included in this report for additional information.


(4)	Includes annual expenditure requirements under operating leases. Our required capital expenditures decreased $1.5 million between December 31, 2018 and March 31, 2019.

We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined therein), or upon a change of control of the Company (as defined therein). The maximum contingent liability under these agreements is approximately $1.7 million as of March 31, 2019. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee.

Results of Operations

The following tables present the unaudited interim consolidated statements of operations and related data for the three month periods ended March 31, 2019 and 2018:



(in thousands)	Three Months Ended March 31,
	2019			2018			Change			%
PATIENT REVENUES, net	$	134,353		$	141,285		$	(6,932	)	(4.9	)%
EXPENSES:
Operating	108,113			112,278			(4,165		)	(3.7	)%
Lease and rent expense	15,804			13,713			2,091			15.2	%
Professional liability	3,421			2,775			646			23.3	%
General and administrative	7,513			8,139			(626		)	(7.7	)%
Depreciation and amortization	2,494			2,881			(387		)	(13.4	)%
Total expenses	137,345			139,786			(2,441		)	(1.7	)%
OPERATING INCOME (LOSS)	(2,992		)	1,499			(4,491		)	N/M
OTHER INCOME (EXPENSE):
Other income	160			51			109			100.0	%
Interest expense, net	(1,460		)	(1,669		)	209			12.5	%
Total other expenses	(1,300		)	(1,618		)	318			19.7	%
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(4,292		)	(119		)	(4,173		)	N/M
BENEFIT FOR INCOME TAXES	955			38			917			N/M
LOSS FROM CONTINUING OPERATIONS	$	(3,337	)	$	(81	)	$	(3,256	)	N/M

N/M = Not Meaningful



Percentage of Net Revenues	Three Months Ended March 31,
	2019		2018
PATIENT REVENUES, net	100.0	%	100.0	%
EXPENSES:
Operating	80.5		79.5
Lease and rent expense	11.8		9.7
Professional liability	2.5		2.0
General and administrative	5.6		5.8
Depreciation and amortization	1.9		2.0
Total expenses	102.3		99.0
OPERATING INCOME (LOSS)	(2.3	)	1.0
OTHER INCOME (EXPENSE):
Other income	0.1		—
Interest expense, net	(1.0	)	(1.2	)
Total other expenses	(0.9	)	(1.2	)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(3.2	)	(0.2	)
BENEFIT FOR INCOME TAXES	0.7		—
LOSS FROM CONTINUING OPERATIONS	(2.5	)%	(0.2	)%

Three Months Ended March 31, 2019 Compared With Three Months Ended March 31, 2018

Patient Revenues

Patient revenues were $134.4 million and $141.3 million for the three months ended March 31, 2019 and 2018, respectively, a decrease of $6.9 million. The following summarizes the revenue fluctuations attributable to changes in our portfolio (in thousands):



	Three Months Ended March 31,
	2019		2018		Change
Same-store revenue	$	134,353	$	136,571	$	(2,218	)
2018 disposition revenue	—		4,714		$	(4,714	)
Total revenue	$	134,353	$	141,285	$	(6,932	)

The three Kentucky centers we sold in December 2018 contributed $4.7 million of the $6.9 million patient revenues decrease. Our same-store patient revenues decreased by $2.2 million. Our average Medicaid and Medicare rates per patient day for the first quarter of 2019 increased compared to the first quarter of 2018, resulting in increases in revenue of $1.7 million and $0.1 million, respectively, or 2.5% and 0.3%, respectively. Our Hospice average daily census for the first quarter of 2019 increased 15.8%, resulting in $1.0 million in additional revenue. Conversely, our Medicare, Medicaid and Private average daily census for the first quarter of 2019 decreased 13.4%, 0.1% and 10.1%, respectively, resulting in revenue losses of $4.1 million, $0.1 million and $1.1 million, respectively. Our ancillary revenue for the first quarter of 2019 increased $0.3 million.

The following table summarizes key revenue and census statistics for continuing operations for each period:



	Three Months Ended March 31,
	2019			2018
Skilled nursing occupancy	78.5		%	79.9		%
As a percent of total census:
Medicare census	10.1		%	11.6		%
Medicaid census	68.7		%	67.9		%
Managed Care census	4.8		%	4.5		%
As a percent of total revenues:
Medicare revenues	18.6		%	21.1		%
Medicaid revenues	47.3		%	45.2		%
Managed Care revenues	10.6		%	10.1		%
Average rate per day:
Medicare	$	457.10		$	455.72
Medicaid	$	181.13		$	176.78
Managed Care	$	394.55		$	391.96

Operating Expense

Operating expense decreased in the first quarter of 2019 to $108.1 million as compared to $112.3 million in the first quarter of 2018. Operating expense increased as a percentage of revenue at 80.5% for the first quarter of 2019 as compared to 79.5% for the first quarter of 2018. The following table summarizes the expense increases attributable to changes in our portfolio (in thousands):



	Three Months Ended March 31,
	2019		2018		Change
Same-store operating expense	$	108,113	$	109,101	$	(988	)
2018 disposition operating expenses	—		3,177		(3,177		)
Total expense	$	108,113	$	112,278	$	(4,165	)

The three Kentucky centers we sold in December 2018 contributed $3.2 million of the $4.2 million operating expense decrease. Our same-store operating expenses decreased by $1.0 million, which is mostly attributable to favorable variances in nursing and ancillary costs and salaries and related taxes of $0.6 million and $0.6 million, respectively, in first quarter of 2019 compared to the first quarter of 2018. This was partially offset by unfavorable variances in dietary costs and maintenance and utilities expense of $0.2 million and $0.1 million, respectively, in first quarter of 2019 compared to the first quarter of 2018.

One of the largest components of operating expenses is wages, which decreased from $67.1 million in the first quarter of 2018 to $65.1 million during the first quarter of 2019.

Lease Expense

Lease expense in the first quarter of 2019 increased to $15.8 million as compared to $13.7 million in the first quarter of 2018. The increase in lease expense was due to rent increases resulting from the new master lease agreement with Omega Healthcare Investors and the impact of non-cash straight-line expense.

Professional Liability

Professional liability expense was $3.4 million and $2.8 million in the first quarters of 2019 and 2018, respectively. Our cash expenditures for professional liability costs of continuing operations were $1.9 million and $1.1 million for the first quarters of 2019 and 2018, respectively. Professional liability expense fluctuates based on the results of our third-party professional liability actuarial studies and cash expenditures are incurred to defend and settle existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

General and Administrative Expense

General and administrative expense was $7.5 million in the first quarter of 2019 as compared to $8.1 million in the first quarter of 2018. General and administrative expense decreased as a percentage of revenue to 5.6% in the first quarter of 2019 from 5.8% in the first quarter of 2018. The change in general and administrative expense is attributable to a decrease in salaries and related taxes of $0.8 million in the first quarter of 2019 as compared to the first quarter of 2018.

Depreciation and Amortization

Depreciation and amortization expense was $2.5 million in the first quarter of 2019 as compared to $2.9 million in the first quarter of 2018. The decrease in depreciation expense relates to the dispositions of Fulton, Clinton and Glasgow in the fourth quarter of 2018. See Note 10, "Business Developments and Other Significant Transactions" to the interim consolidated financial statements.

Interest Expense, Net

Interest expense was $1.5 million in the first quarter of 2019 and $1.7 million first quarter of 2018. The decrease of $0.2 million is due to a decrease in the outstanding borrowings on our loan facilities.

Loss from Continuing Operations before Income Taxes; Loss from Continuing Operations per Common Share

As a result of the above, continuing operations reported a loss of $4.3 million before income taxes for the first quarter of 2019 as compared to a loss of $0.1 million for the first quarter of 2018. The benefit for income taxes was $1.0 million for the first quarter of 2019, and the benefit for income taxes was $0.1 million for the first quarter of 2018. Both basic and diluted loss per common share from continuing operations were $0.52 for the first quarter of 2019 as compared to both basic and diluted loss per common share from continuing operations of $0.01 in the first quarter of 2018.

Liquidity and Capital Resources

Liquidity

Our primary source of liquidity is the net cash flow provided by the operating activities of our centers. We believe that these internally generated cash flows will be adequate to service existing debt obligations and fund required capital expenditures. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long-term. Options for our use of cash include, but are not limited to, capital improvements, purchase of additional shares of our common stock, acquisitions, payment of existing debt obligations as well as initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.

Net cash provided by operating activities of continuing operations totaled $0.4 million for the three months ended March 31, 2019, compared to net cash provided by operating activities of continuing operations of $5.2 million in the same period of 2018. The primary driver of the decrease in cash provided by operating activities from continuing operations is due to our net loss of $3.3 million for the three months ended March 31, 2019, compared to net loss of $0.1 million in the same period of 2018, primarily due to $1.7 million of additional rent expense from the straight-line impact of the new Omega master lease, which commenced in the fourth quarter 2018.

Our cash expenditures related to professional liability claims of continuing operations were $1.9 million and $1.1 million for three months ended March 31, 2019 and 2018, respectively. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our inability to meet all of our cash needs as they become due.

Investing activities of continuing operations used cash of $1.5 million and $2.0 million for the three months ended in 2019 and 2018, respectively. The cash used for investing activities relates to the purchase of property and equipment at the centers we operate.

Financing activities of continuing operations provided cash of $0.9 million and $0.2 million for the three months ended March 31, 2019 and 2018, respectively. The fluctuation is primarily due to the dividend and preferred stock payments in 2018.

Professional Liability

The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC, which has issued a policy insuring claims made against all of the Company's nursing centers in Florida and Tennessee, and several of the Company's nursing centers in Alabama, Kentucky, Ohio, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary

As of March 31, 2019, we have recorded total liabilities for reported and settled professional liability claims and estimates for incurred, but unreported claims of $24.6 million. Our calculation of this estimated liability is based on the Company's best estimate of the likelihood of adverse judgments with respect to any asserted claim; however, a significant judgment could be entered against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.

Capital Resources

As of March 31, 2019, we had $75.5 million of outstanding long-term debt and finance lease obligations. The $75.5 million total includes $0.8 million in finance lease obligations and $16.5 million currently outstanding on the revolving credit facility. The balance of the long-term debt is comprised of $58.2 million owed on our mortgage loan, which includes $51.3 million on the term loan facility, $6.9 million on the acquisition loan facility.

On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increases the Company's borrowing capacity to $100.0 million allocated between a $72.5 million Mortgage Loan ("Amended Mortgage Loan") and a $27.5 million Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60 million term loan facility and a $12.5 million acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2.2 million and are being amortized over the five-year term of the agreements.

Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $72.5 million with a five-year maturity through February 26, 2021, and a $27.5 million Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30.0 million. As of March 31, 2019, the interest rate related to the Amended Mortgage Loan was 6.50%. The Amended Mortgage Loan is secured by fifteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.

Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27.5 million in the Amended Revolver to $52.3 million; provided that the maximum revolving facility be reduced to $42.3 million on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $42.3 million.

On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modifies the terms of the Amended Revolving Agreement by increasing the Company’s letter of credit sublimit from $10.0 million to $15.0 million.

Effective June 30, 2017, the Company entered into a Second Amendment (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amends the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7.5 million.

Effective December 1, 2018, the Company entered into the Sixth Amendment ("Sixth Revolver Amendment") to amend the Amended Revolver. The Sixth Amendment decreased the Amended Revolver capacity from $52.3 million to $42.3 million. The Company also applied $4.9 million of net proceeds from the sale of the Kentucky centers to the outstanding borrowing under the Amended Revolver.

Effective December 1, 2018, the Company executed a Fourth Amendment (the "Fourth Term Amendment") to amend the Amended Mortgage Loan. The Company applied $11.1 million and $2.1 million of net proceeds from the sale of the Kentucky centers to the Term Loan and Acquisition Loan, respectively. Additionally, we amended the Acquisition Loan availability to include a reserve of $2.1 million, and therefore, our borrowing capacity is $10.4 million. For further discussion of the sale of the Kentucky centers, refer to Note 10, "Business Development and Other Significant Transactions."

As of March 31, 2019, the Company had $16.5 million borrowings outstanding under the Amended Revolver compared to $15.0 million outstanding as of December 31, 2018. The interest rate related to the Amended Revolver was 6.50% as of March 31, 2019. The outstanding borrowings on the revolver were used primarily for temporary working capital requirements. Annual fees for letters of credit issued under the Amended Revolver are 3.00% of the amount outstanding. The Company has four letters of credit with a total value of $13.6 million outstanding as of March 31, 2019. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $36.7 million, the balance available for borrowing under the Amended Revolver was $6.6 million at March 31, 2019.

Our lending agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. We are in compliance with all such covenants at March 31, 2019.

Our calculated compliance with financial covenants is presented below:



	Requirement	Level at March 31, 2019
Minimum fixed charge coverage ratio	1.01:1.00	1.04:1.00
Minimum adjusted EBITDA	$13.0 million	$18.3 million
EBITDAR (mortgaged centers)	$10.0 million	$15.4 million
Current ratio (as defined in agreement)	1.00:1.00	1.28:1.00

As part of the debt agreements entered into in February 2016, we amended our interest rate swap agreement with a member of the bank syndicate as the counterparty. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and carries an initial notional amount of $30.0 million. The interest rate swap agreement requires us to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to us based on LIBOR on the same notional amounts. We entered into the interest rate swap agreement to mitigate the variable interest rate risk on our outstanding mortgage borrowings.

Off-Balance Sheet Arrangements

We have four letters of credit outstanding with an aggregate value of approximately $13.6 million as of March 31, 2019. The letters of credit serve as a security deposits for certain center leases. These letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility.

Forward-Looking Statements

The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our interim consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "will," "should," "expect," "believe," "estimate," "intend," and similar words indicating possible future expectations, events or actions. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to:


•	our ability to successfully integrate the operations of new nursing centers, as well as successfully operate all of our centers,


•	our ability to increase census at our centers and occupancy rates at our centers,


•	changes in governmental reimbursement, including the new Patient-Driven Payment Model to be implemented in the fall of 2019


•	government regulation,


•	the impact of the Affordable Care Act, efforts to repeal or further modify the Affordable Care Act, and other health care reform initiatives,


•	any increases in the cost of borrowing under our credit agreements,


•	our ability to comply with covenants contained in those credit agreements,


•	our ability to comply with the terms of our master lease agreements,


•	our ability to renew or extend our leases at or prior to the end of the existing lease terms,


•	the outcome of professional liability lawsuits and claims,


•	our ability to control ultimate professional liability costs,


•	the accuracy of our estimate of our anticipated professional liability expense,


•	the impact of future licensing surveys,


•	the outcome of proceedings alleging violations of state or Federal False Claims Acts,


•	laws and regulations governing quality of care or other laws and regulations applicable to our business including HIPAA and laws governing reimbursement from government payors,


•	the costs of investing in our business initiatives and development,


•	our ability to control costs,


•	our ability to attract and retain qualified healthcare professionals,


•	changes to our valuation of deferred tax assets,


•	changing economic and competitive conditions,


•	changes in anticipated revenue and cost growth,


•	changes in the anticipated results of operations,


•	the effect of changes in accounting policies as well as others.

Investors also should refer to the risks identified in this “Management's Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Part I. Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2018, for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of March 31, 2019, we had outstanding borrowings of approximately $74.7 million, $47.2 million of which was subject to variable interest rates. In connection with our February 2016 financing agreement, we entered into an interest rate swap with an initial notional amount of $30.0 million to mitigate the floating interest rate risk of a portion of such borrowing. In the event that interest rates were to change 1%, the impact on future pre-tax cash flows would be approximately $0.5 million annually, representing the impact of increased or decreased interest expense on variable rate debt.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of March 31, 2019. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is properly recorded, processed, summarized and reported within the time periods required by the Securities and Exchange Commission’s rules and forms. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures that, by their nature, can provide only reasonable assurance regarding management’s control objectives. Management does not expect that its disclosure controls and procedures will prevent all errors and fraud. A control system, irrespective of how well it is designed and operated, can only provide reasonable assurance, and cannot guarantee that it will succeed in its stated objectives.

Based on an evaluation of the effectiveness of the design and operation of disclosure controls and procedures, our chief executive officer and chief financial officer concluded that, as of March 31, 2019, our disclosure controls and procedures were effective in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.

Changes in Internal Control Over Financial Reporting

We completed certain changes to our accounting processes related to our implementation of ASC 842, which was adopted on January 1, 2019. We updated our control activities for the adoption of the new accounting standard and the new accounting processes and methodologies established to evaluate leases and service agreements under ASC 842.

Other than the items described above, there have been no changes to our internal control over financial reporting during the quarter ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits alleging malpractice, negligence, violations of false claims acts, product liability, or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and are potentially subject to the increased scrutiny of regulators for issues related to compliance with health care fraud and abuse laws and with respect to the quality of care provided to residents of our facilities. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.

As of March 31, 2019, we are engaged in 78 professional liability lawsuits. Twenty-seven lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted. We have limited, and sometimes no, professional liability insurance with regard to most of these claims. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.

In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Center”). The Company answered the original complaint in 2009, and there was no other activity in the case until May 2017. At that time, plaintiff filed an amended complaint asserting new causes of action. The amended complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Center over a multi-year period by failing to meet minimum staffing requirements, failing to otherwise adequately staff the Center and failing to provide a clean and safe living environment in the Center. The Company filed an answer to the amended complaint denying plaintiffs’ allegations and asked the Court to dismiss the new causes of action asserted in the amended complaint because the Company was prejudiced by plaintiff’s long delay in filing the amended complaint. The Court has not yet ruled on the motion to dismiss, so the lawsuit remains in its early stages and has not yet been certified by the court as a class action. The Company intends to defend the lawsuit vigorously.

We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. An unfavorable outcome in any of these lawsuits, any of our professional liability actions, any regulatory action, or any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims Act law could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.

ITEM 1A. RISK FACTORS.

In addition to the other information contained in this Quarterly Report, the risks and uncertainties that we believe could materially affect our business, financial condition or future results and are most important for you to consider are discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 28, 2019. Additional risks and uncertainties which are not presently known to us, which we currently deem immaterial or which are similar to those faced by other companies in our industry or business in general, may also materially and adversely affect any of our business, financial position or future results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURE.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS

The following exhibits are filed as part of this report on Form 10-Q.




Exhibit Number			Description of Exhibits
3.1			Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).

3.2			Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2006).

3.3			Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).

3.4			Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company’s annual report on Form 10-K for the year ended December 31, 2007).

3.5			Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company’s Form 8-A filed March 30, 1995 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).

3.6			Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2001).

3.7			Certificate of Ownership and Merger of Diversicare Healthcare Services, Inc. with and into Advocat Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K filed March 14, 2013).

3.8			Amendment to Certificate of Incorporation dated June 9, 2016 (incorporated by reference to Exhibit 3.8 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).

3.9			Bylaw Second Amendment adopted April 14, 2016.

4.1			Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company's Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).

31.1			Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).

31.2			Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).

32			Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).

101.INS			XBRL Instance Document

101.SCH			XBRL Taxonomy Extension Schema Document

101.CAL			XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB			XBRL Taxonomy Extension Labels Linkbase Document

101.PRE			XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




	Diversicare Healthcare Services, Inc.

May 2, 2019

	By:	/s/ James R. McKnight, Jr.
		James R. McKnight, Jr.
		President and Chief Executive Officer, Principal Executive Officer and
		An Officer Duly Authorized to Sign on Behalf of the Registrant

	By:	/s/ Kerry D. Massey
		Kerry D. Massey
		Executive Vice President and Chief Financial Officer and
		An Officer Duly Authorized to Sign on Behalf of the Registrant

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	Apr. 29, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Diversicare Healthcare Services, Inc.
Entity Central Index Key	0000919956
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		6,682,260

INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, shares authorized (shares)	20,000,000	20,000,000
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (shares)	6,914,000	6,751,000
Common stock, shares outstanding (shares)	6,682,000	6,519,000
Treasury stock, shares (shares)	232,000	232,000

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
PATIENT REVENUES, net	$ 134,353	$ 141,285
EXPENSES:
Operating	108,113	112,278
Lease and rent expense	15,804	13,713
Professional liability	3,421	2,775
General and administrative	7,513	8,139
Depreciation and amortization	2,494	2,881
Total expenses	137,345	139,786
OPERATING INCOME (LOSS)	(2,992)	1,499
OTHER INCOME (EXPENSE):
Other income	160	51
Interest expense, net	(1,460)	(1,669)
Total other expense	(1,300)	(1,618)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(4,292)	(119)
BENEFIT FOR INCOME TAXES	955	38
LOSS FROM CONTINUING OPERATIONS	(3,337)	(81)
LOSS FROM DISCONTINUED OPERATIONS:
Operating loss, net of tax expense of $0 and $11, respectively	(9)	(22)
NET LOSS	$ (3,346)	$ (103)
Per common share – basic
Continuing operations (in dollars per share)	$ (0.52)	$ (0.01)
Discontinued operations (in dollars per share)	0.00	0.00
Net income (loss) per common share – basic (dollars per share)	(0.52)	(0.01)
Per common share – diluted
Continuing operations (in dollars per share)	(0.52)	(0.01)
Discontinued operations (in dollars per share)	0.00	0.00
Net income (loss) per common share – diluted (dollars per share)	(0.52)	(0.01)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share)	$ 0	$ 0.055
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (shares)	6,424	6,314
Diluted (shares)	6,424	6,314

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Tax expense (benefit), effect on operating loss	$ 0	$ 11

INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
NET LOSS	$ (3,346)	$ (103)
OTHER COMPREHENSIVE INCOME:
Change in fair value of cash flow hedge, net of tax	(63)
Change in fair value of cash flow hedge, net of tax		322
Less: reclassification adjustment for amounts recognized in net loss	0
Less: reclassification adjustment for amounts recognized in net loss		(114)
Total other comprehensive income (loss)	(63)	208
COMPREHENSIVE INCOME (LOSS)	$ (3,409)	$ 105


(a)	fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(b)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

INTERIM CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 2,465	$ 2,685
Receivables	63,864	66,257
Self-insurance receivables	1,775	4,475
Other receivables	1,169	1,191
Prepaid expenses and other current assets	4,489	4,728
Income tax refundable	553	1,115
Current assets of discontinued operations	0	86
Total current assets	74,315	80,537
PROPERTY AND EQUIPMENT, at cost	139,954	138,460
Less accumulated depreciation and amortization	(87,666)	(85,361)
Property and equipment, net	52,288	53,099
OTHER ASSETS:
Deferred income taxes, net	17,022	15,851
Deferred leasehold costs	0	206
Operating lease assets	377,799
Acquired leasehold interest, net	6,136	6,307
Other noncurrent assets	3,309	3,244
Total other assets	404,266	25,608
Total assets	530,869	159,244
CURRENT LIABILITIES:
Current portion of long-term debt and finance lease obligations, net	10,390	12,449
Trade accounts payable	15,137	15,659
Current liabilities of discontinued operations	0	86
Current portion of operating lease liabilities	22,205
Accrued expenses:
Payroll and employee benefits	17,643	19,471
Self-insurance reserves, current portion	10,881	13,158
Provider taxes	2,381	2,394
Other current liabilities	6,697	7,128
Total current liabilities	85,334	70,345
NONCURRENT LIABILITIES:
Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	64,069	60,984
Operating lease liabilities, less current portion	362,094
Self-insurance reserves, noncurrent portion	15,875	16,057
Litigation contingency	6,400	6,400
Other noncurrent liabilities	1,522	6,656
Total noncurrent liabilities	449,960	90,097
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ DEFICIT:
Common stock, authorized 20,000 shares, $.01 par value, 6,914 and 6,751 shares issued, and 6,682 and 6,519 shares outstanding, respectively	69	68
Treasury stock at cost, 232 shares of common stock	(2,500)	(2,500)
Paid-in capital	23,594	23,413
Accumulated deficit	(26,362)	(23,016)
Accumulated other comprehensive income	774	837
Total shareholders’ deficit	(4,425)	(1,198)
Total liabilities and shareholder's equity	$ 530,869	$ 159,244

INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Balance (in shares) at Dec. 31, 2017		6,687	232
Balance at Dec. 31, 2017	$ 6,462	$ 67	$ (2,500)	$ 22,720	$ (14,534)	$ 709
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(103)				(103)
Common stock dividends declared	(350)			13	(363)
Issuance/redemption of equity grants, net (in shares)		86
Issuance/redemption of equity grants, net	(78)	$ 1		(79)
Interest rate cash flow hedge	208					208
Stock-based compensation	236			236
Balance (in shares) at Mar. 31, 2018		6,773	232
Balance at Mar. 31, 2018	6,375	$ 68	$ (2,500)	22,890	(15,000)	917
Balance (in shares) at Dec. 31, 2018		6,751	232
Balance at Dec. 31, 2018	(1,198)	$ 68	$ (2,500)	23,413	(23,016)	837
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(3,346)				(3,346)
Issuance/redemption of equity grants, net (in shares)		163
Issuance/redemption of equity grants, net	42	$ 1		41
Interest rate cash flow hedge	(63)					(63)
Stock-based compensation	140			140
Balance (in shares) at Mar. 31, 2019		6,914	232
Balance at Mar. 31, 2019	$ (4,425)	$ 69	$ (2,500)	$ 23,594	$ (26,362)	$ 774

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS	$ (3,346)	$ (103)
Discontinued operations	(9)	(22)
Loss from continuing operations	(3,337)	(81)
Adjustments to reconcile loss from continuing operations to net cash provided by operating activities:
Depreciation and amortization	2,494	2,881
Deferred income tax provision (benefit)	(1,090)	0
Provision for self-insured professional liability, net of cash payments	1,444	956
Stock-based and deferred compensation	156	284
Provision (benefit) for leases in excess of cash payments	1,280	(453)
Other	335	140
Changes in assets and liabilities affecting operating activities:
Receivables, net	5,315	2,017
Prepaid expenses and other assets	(2,966)	(439)
Trade accounts payable and accrued expenses	(3,269)	(86)
Net cash provided by continuing operations	362	5,219
Discontinued operations	(9)	(474)
Net cash provided by operating activities	353	4,745
NET CASH FLOWS USED IN INVESTING ACTIVITIES:
Purchases of property and equipment	(1,512)	(2,012)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt and finance lease obligations	(1,112)	(4,762)
Proceeds from issuance of debt	2,049	5,651
Financing costs	(40)	(132)
Issuance and redemption of employee equity awards	42	(78)
Payment of common stock dividends	0	(350)
Payment for preferred stock restructuring	0	(168)
Net cash provided by continuing operations	939	161
Discontinued operations	0	0
Net cash provided by financing activities	939	161
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(220)	2,894
CASH AND CASH EQUIVALENTS, beginning of period	2,685	3,524
CASH AND CASH EQUIVALENTS, end of period	2,465	6,418
SUPPLEMENTAL INFORMATION:
Cash payments of interest	1,289	1,432
Cash receipts of income taxes	(426)	(16)
SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Acquisition of equipment through finance leases	49	$ 0
Acquisition of operating leases through adoption of ASC 842	$ 389,403

BUSINESS	3 Months Ended
BUSINESS	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	BUSINESS Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas. As of March 31, 2019, the Company’s continuing operations consist of 72 nursing centers with 8,214 licensed nursing beds. The Company owns 15 and leases 57 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 429 licensed assisted and residential living beds.

RECENT ACCOUNTING GUIDANCE	3 Months Ended
RECENT ACCOUNTING GUIDANCE	Mar. 31, 2019
Accounting Policies [Abstract]
RECENT ACCOUNTING GUIDANCE	RECENT ACCOUNTING GUIDANCE Recent Accounting Standards Adopted by the Company In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short-term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make (and the Company chose to utilize) an accounting policy election by asset class not to recognize ROU assets and lease liabilities, which would generally result in lease expense for these short term leases being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company elected to use the optional expedient to reflect adoption in the period of adoption (January 1, 2019) rather than the earliest period presented. The Company also elected the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The adoption of the new standard resulted in the recording of net lease assets and lease liabilities of $384,187 and $389,403, respectively, as of January 1, 2019. The standard did not materially impact our consolidated net earnings and had no impact on cash flows. See Note 6, "Leases" for a discussion regarding leases under the new standard. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvement to Nonemployee Share-Based Payment Accounting, which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. The standard is effective for fiscal years beginning after December 15, 2018. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. The new guidance is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The adoption of ASC 606 represents a change in accounting principle that more closely aligns revenue recognition with the delivery of the Company's services. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The new guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows. Accounting Standards Recently Issued But Not Yet Adopted by the Company In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements of fair value measurements under Topic 820. The standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. In October 2018, the FASB issued ASU No. 2018-16, Derivatives and Hedging (Topic 805): Inclusion of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. The ASU amends ASC 815 to add the OIS rate based on the SOFR as a fifth US benchmark interest rate. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.

LONG-TERM DEBT AND INTEREST RATE SWAP	3 Months Ended
LONG-TERM DEBT AND INTEREST RATE SWAP	Mar. 31, 2019
Debt Disclosure [Abstract]
LONG-TERM DEBT AND INTEREST RATE SWAP	LONG-TERM DEBT AND INTEREST RATE SWAP The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five-year term of the agreements. Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five-year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000. The Amended Mortgage Loan balance was $58,150 as of March 31, 2019, consisting of $51,250 on the term loan facility with an interest rate of 6.50% and $6,900 on the acquisition loan facility with an interest rate of 7.25%. The Amended Mortgage Loan is secured by fifteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $42,250. On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Revolving Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000. Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500. Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter. Effective December 1, 2018, the Company entered into the Sixth Amendment ("Sixth Revolver Amendment") to amend the Amended Revolver. The Sixth Amendment decreased the Amended Revolver capacity from $52,250 to $42,250. The Company also applied $4,947 of net proceeds from the sale of the Kentucky centers to the outstanding borrowings under the Amended Revolver. Effective December 1, 2018, the Company executed a Fourth Amendment (the "Fourth Term Amendment") to amend the Amended Mortgage Loan. The Company applied $11,100 and $2,100 of net proceeds from the sale of the Kentucky centers to the Term Loan and Acquisition Loan, respectively. Additionally, we amended the Acquisition Loan availability to include a reserve of $2,100, and therefore, our borrowing capacity is $10,400. For further discussion of the sale of the Kentucky centers, refer to Note 10, "Business Development and Other Significant Transactions." As of March 31, 2019, the Company had $16,500 borrowings outstanding under the Amended Revolver compared to $15,000 outstanding as of December 31, 2018. The interest rate related to the Amended Revolver was 6.50% as of March 31, 2019. The outstanding borrowings on the revolver were used primarily for temporary working capital requirements. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has four letters of credit with a total value of $13,594 outstanding as of March 31, 2019. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $36,679 the balance available for borrowing under the Amended Revolver was $6,585 at March 31, 2019. The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at March 31, 2019. Interest Rate Swap Transaction As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $27,450 as of March 31, 2019. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount. The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at March 31, 2019, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of $230 at March 31, 2019. The fair value of the interest rate swap is included in “other noncurrent assets” on the Company’s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at March 31, 2019 is $161 net of the income tax provision of $69. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Mar. 31, 2019
Health Care Organizations [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Professional Liability and Other Liability Insurance The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary. Reserve for Estimated Self-Insured Professional Liability Claims Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,625 and $27,201 as of March 31, 2019 and December 31, 2018, respectively. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period. The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods. On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. As of March 31, 2019, the Company is engaged in 78 professional liability lawsuits. Twenty-seven lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $1,906 and $1,093 for the three months ended March 31, 2019 and 2018, respectively. The Company follows the accounting guidance in ASC Topic 954 that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" and "Other Noncurrent Assets" on the Consolidated Balance Sheet. As of March 31, 2019 there are estimated insurance recovery receivables of $2,125. There were no estimated insurance recovery receivables as of March 31, 2018. Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made. Civil Investigative Demand ("CID") In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA"). In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. Discussions continue with the DOJ regarding settlement of this investigation. The Company denies any wrong doing and is prepared to vigorously defend its actions if a settlement is not reached. The Company accrued $6,400 as a contingent liability in connection with this matter during the three months ended September 30, 2018, but the Company cannot predict whether a settlement can be achieved, the outcome of the litigation if there is no settlement or the length of time necessary to conclude this matter. Accordingly, the contingent liability has been classified as a noncurrent liability in the accompanying interim consolidated balance sheets. The Company’s ultimate ability to settle this investigation will depend on several factors, including whether the amount and terms of an acceptable settlement can be reached with the DOJ, the Company’s assessment of the risks of litigating this case and the effect of protracted litigation or settlement terms on the Company’s business plans. Because the outcome of this investigation and related settlement discussions remain uncertain, there is a reasonable possibility that the amount ultimately incurred in connection with the resolution of this matter could differ materially from the current accrual, as the Company cannot, at this time, estimate the possible range of loss that may result from either a settlement or litigation of this matter. The ultimate outcome of this litigation could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to the practices of some of its employees with respect to PAEs and PASRRs, and the Company provided documents responsive to this subpoena and coordinated examinations of certain employees of the Company. The Company understands that this criminal investigation has been closed, subject to re-opening at the discretion of the government. Other Insurance With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. From the period from July 1, 2008 through March 31, 2019, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $688 and $618 at March 31, 2019 and December 31, 2018, respectively.. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,458 and $1,258 as of March 31, 2019 and December 31, 2018, respectively. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred. As of March 31, 2019, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,444 at March 31, 2019. The differences between actual settlements and reserves are included in expense in the period finalized.

BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS	BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS 2018 Assets Sold On October 30, 2018 the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation, LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operation of Diversicare of Fulton, LLC, Diversicare of Clinton, LLC and Diversicare of Glasgow, LLC (the "Kentucky Properties"). On December 1, 2018, the Company completed the sale of the Kentucky Properties with the Buyers for a purchase price of $18,700. This transaction did not meet the accounting criteria to be reported as a discontinued operation. The carrying value of these centers' assets were $13,331, resulting in a gain of $4,825, with remaining proceeds for miscellaneous closing costs. The proceeds were used to relieve debt, which is required under the terms of the Company's Amended Mortgage Loan and Amended Revolver. Refer to Note 5, "Long-term Debt, Interest Rate Swap" for more information on this transaction. 2018 New Master Lease Agreement On October 1, 2018, the Company entered into a New Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor") to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operated 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and Omega consolidates the leases for all 34 centers under one New Master Lease. The Lease has an initial term of twelve years with two 10-year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019.

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Mar. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Effective April 1, 2019, the Company expanded it's participation in the Texas Quality Incentive Payment Program (“QIPP”) as administered by the Texas Health and Human Services Commission. Four skilled nursing centers previously operated by the Company entered into a transaction with a Texas medical district participating in the QIPP, providing for the transfer of the provider license from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district.

CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting	The interim consolidated financial statements for the three month periods ended March 31, 2019 and 2018, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2019, and the results of operations for the three month periods ended March 31, 2019 and 2018, changes in shareholders' equity (deficit) for the three month periods ended March 31, 2019 and 2018, and cash flows for the three month periods ended March 31, 2019 and 2018. The Company’s balance sheet information at December 31, 2018, was derived from its audited consolidated financial statements as of December 31, 2018. Effective January 1, 2019, we adopted the requirements of Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), as discussed in Notes 3 and 6 to the interim consolidated financial statements. Effective January 1, 2018, we adopted the requirements of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standards. The results of operations for the periods ended March 31, 2019 and 2018 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
Recent Accounting Standards Adopted and Not Adopted by the Company	Recent Accounting Standards Adopted by the Company In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short-term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make (and the Company chose to utilize) an accounting policy election by asset class not to recognize ROU assets and lease liabilities, which would generally result in lease expense for these short term leases being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company elected to use the optional expedient to reflect adoption in the period of adoption (January 1, 2019) rather than the earliest period presented. The Company also elected the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The adoption of the new standard resulted in the recording of net lease assets and lease liabilities of $384,187 and $389,403, respectively, as of January 1, 2019. The standard did not materially impact our consolidated net earnings and had no impact on cash flows. See Note 6, "Leases" for a discussion regarding leases under the new standard. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvement to Nonemployee Share-Based Payment Accounting, which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. The standard is effective for fiscal years beginning after December 15, 2018. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. The new guidance is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The adoption of ASC 606 represents a change in accounting principle that more closely aligns revenue recognition with the delivery of the Company's services. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The new guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows. Accounting Standards Recently Issued But Not Yet Adopted by the Company In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements of fair value measurements under Topic 820. The standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. In October 2018, the FASB issued ASU No. 2018-16, Derivatives and Hedging (Topic 805): Inclusion of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. The ASU amends ASC 815 to add the OIS rate based on the SOFR as a fifth US benchmark interest rate. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
Revenue Recognition	On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The adoption of ASC 606 represents a change in accounting principle that more closely aligns revenue recognition with the delivery of the Company's services. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps: Step 1: Identify the contract with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation. The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes. The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less. The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

BUSINESS (Details)	Mar. 31, 2019 state center bed	Oct. 01, 2018 center
Accounting Policies [Line Items]
Number of states in which entity operates \| state	10
Number of nursing centers \| center	72
Number of licensed nursing beds	8,214
Number of nursing center facilities owned \| center	15
Number of nursing center facilities leased \| center	57	34
Number of licensed assisted and residential living beds	429
Minimum
Accounting Policies [Line Items]
Number of licensed nursing beds per center	48
Maximum
Accounting Policies [Line Items]
Number of licensed nursing beds per center	320

RECENT ACCOUNTING GUIDANCE RECENT ACCOUNTING GUIDANCE (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019
Accounting Policies [Abstract]
Net lease assets	$ 378,844	$ 384,187
Lease liabilities	$ 385,148	$ 389,403

REVENUE RECOGNITION - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Total revenues	$ 134,353
Total revenues, as a percent	100.00%
Medicaid
Disaggregation of Revenue [Line Items]
Total revenues	$ 63,531
Total revenues, as a percent	47.30%
Medicare
Disaggregation of Revenue [Line Items]
Total revenues	$ 25,055
Total revenues, as a percent	18.60%
Managed Care
Disaggregation of Revenue [Line Items]
Total revenues	$ 14,175
Total revenues, as a percent	10.60%
Private Pay and other
Disaggregation of Revenue [Line Items]
Total revenues	$ 31,592
Total revenues, as a percent	23.50%
Calculated under Revenue Guidance in Effect before Topic 606
Disaggregation of Revenue [Line Items]
Total revenues		$ 141,285
Total revenues, as a percent		100.00%
Calculated under Revenue Guidance in Effect before Topic 606 \| Medicaid
Disaggregation of Revenue [Line Items]
Total revenues		$ 63,886
Total revenues, as a percent		45.20%
Calculated under Revenue Guidance in Effect before Topic 606 \| Medicare
Disaggregation of Revenue [Line Items]
Total revenues		$ 29,751
Total revenues, as a percent		21.10%
Calculated under Revenue Guidance in Effect before Topic 606 \| Managed Care
Disaggregation of Revenue [Line Items]
Total revenues		$ 14,212
Total revenues, as a percent		10.10%
Calculated under Revenue Guidance in Effect before Topic 606 \| Private Pay and other
Disaggregation of Revenue [Line Items]
Total revenues		$ 33,436
Total revenues, as a percent		23.60%

REVENUE RECOGNITION - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	$ 63,864	$ 66,257
Medicaid
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	25,971	27,532
Medicare
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	13,249	15,706
Managed Care
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	9,083	8,126
Private Pay and other
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	$ 15,561	$ 14,893

LONG-TERM DEBT AND INTEREST RATE SWAP (Details)			3 Months Ended
LONG-TERM DEBT AND INTEREST RATE SWAP (Details)	Dec. 01, 2018 USD ($)	Feb. 26, 2016 USD ($) center	Mar. 31, 2019 USD ($) letter_of_credit	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)	Aug. 01, 2017 USD ($)	Jun. 30, 2017 USD ($)	Dec. 29, 2016 USD ($)	Dec. 28, 2016 USD ($)	Oct. 03, 2016 USD ($)
Line of Credit Facility [Line Items]
Accumulated other comprehensive income (loss)			$ 774,000		$ 837,000
Income tax benefit, interest rate swap			(955,000)	$ (38,000)
Interest rate swap
Line of Credit Facility [Line Items]
Notional amount of interest rate derivatives			$ 27,450,000
Annual fixed rate percentage			5.79%
Net asset based on interest rate swap valuation model			$ 230,000
Accumulated other comprehensive income (loss)			161,000
Income tax benefit, interest rate swap			$ 69,000
Amended and restated credit agreement
Line of Credit Facility [Line Items]
Loan acquisition costs		$ 2,162,000
Number of letters of credit \| letter_of_credit			4
Credit agreement \| Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 100,000,000
Term of agreements		5 years
Mortgage loan \| Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 72,500,000
Term of agreements		5 years
Period of amortization		25 years
Amended mortgage loan balance			$ 58,150,000
Number of owned nursing centers to secure Amended Mortgage Loan \| center		15
Mortgage loan \| Amended and restated credit agreement \| Interest rate swap
Line of Credit Facility [Line Items]
Debt interest rate at period end		5.79%
Amended revolver \| Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity	$ 42,250,000	$ 27,500,000	36,679,000			$ 42,250,000	$ 42,250,000			$ 52,250,000
Fixed charge coverage ratio				1.01
Repayments of lines of credit	4,947,000
Borrowings outstanding			$ 16,500,000		$ 15,000,000
Interest rate during period			6.50%
Balance available for borrowing under revolving credit center			$ 6,585,000
Amended revolver \| Amended and restated credit agreement \| LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage		4.00%
Letter of credit \| Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity								$ 15,000,000	$ 10,000,000
Annual fees for letters of credit issued under Revolver (as a percentage)		3.00%
Mortgage term loan \| Mortgage loan \| Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 60,000,000
Debt interest rate at period end			6.50%
Amended mortgage loan balance			$ 51,250,000
Increase to credit facility limit							$ 7,500,000
Mortgage term loan \| Mortgage loan \| Amended and restated credit agreement \| Interest rate swap \| Designated as hedging instrument
Line of Credit Facility [Line Items]
Notional amount of interest rate derivatives		$ 30,000,000
Mortgage term loan \| Mortgage loan \| Amended and restated credit agreement \| LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage		4.00%
Mortgage term loan \| Amended revolver \| Amended and restated credit agreement
Line of Credit Facility [Line Items]
Repayments of lines of credit	11,100,000
Acquisition loan facility \| Mortgage loan \| Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 12,500,000
Debt interest rate at period end			7.25%
Amended mortgage loan balance			$ 6,900,000
Acquisition loan facility \| Mortgage loan \| Amended and restated credit agreement \| LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage		4.75%
Acquisition loan facility \| Amended revolver \| Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity	10,400,000
Repayments of lines of credit	$ 2,100,000
Omega Healthcare Investors Inc \| Amended revolver \| Amended and restated credit agreement
Line of Credit Facility [Line Items]
Letters of credit security deposit for a lease			$ 13,594,000

LEASES - Narrative (Details)	3 Months Ended
LEASES - Narrative (Details)	Mar. 31, 2019
Lessee, Lease, Description [Line Items]
Other leases renewal term	20 years
Other leases termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Other leases remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Other leases remaining lease term	12 years

LEASES - Balance Sheet Classification (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Jan. 01, 2019
Leases [Abstract]
Finance Lease, Right-of-Use Asset, Accumulated Amortization	$ 1,283
Assets [Abstract]
Operating lease assets	377,799
Finance lease assets	1,045
Total leased assets	378,844	$ 384,187
Liabilities, Current [Abstract]
Current portion of operating lease liabilities	22,205
Finance lease, current	383
Liabilities, Noncurrent [Abstract]
Operating lease liabilities, less current portion	362,094
Finance lease, noncurrent	466
Total lease liabilities	385,148	$ 389,403
Amortization of finance lease assets	$ 67

LEASES - Lease Cost (Details) $ in Thousands	3 Months Ended
LEASES - Lease Cost (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Leases [Abstract]
Operating lease cost	$ 15,804
Finance Lease, Cost [Abstract]
Amortization of finance lease assets	67
Interest on finance lease liabilities	11
Short term lease cost	141
Net lease cost	$ 16,023

LEASES - Maturities of Operating and Financing Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Operating Leases
2019	$ 58,586
2020	59,666
2021	60,856
2022	62,075
2023	63,211
After 2023	305,640
Total lease payments	610,034
Less: Interest	(225,735)
Present value of lease liabilities	384,299
2019		$ 58,291
2020		59,391
2021		60,575
2022		61,808
2023		63,065
After 2023		321,797
Total lease payments		624,927
Finance Leases
2019	429
2020	212
2021	197
2022	100
2023	0
After 2023	0
Total lease payments	938
Less: Interest	(89)
Present value of lease liabilities	849
2018		454
2019		174
2020		173
2021		127
2022		0
After 2022		0
Total lease payments		928
Operating and Finance Lease Liabilities, Payments, Due [Abstract]
2019	59,015	58,745
2020	59,878	59,565
2021	61,053	60,748
2022	62,175	61,935
2023	63,211	63,065
After 2023	305,640	321,797
Total lease payments	610,972	$ 625,855
Less: Interest	(225,824)
Present value of lease liabilities	$ 385,148

LEASES - Other Lease Information (Details) $ in Thousands	3 Months Ended
LEASES - Other Lease Information (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Weighted-average remaining lease term (years)
Operating leases	9 years 9 months 7 days
Finance leases	2 years 7 months 13 days
Weighted-average discount rate
Operating leases	9.90%
Finance leases	6.60%
Operating cash flows from operating leases	$ 14,516
Operating cash flows from finance leases	11
Financing cash flows from finance leases	132
Acquisition of operating leases through adoption of ASC 842	$ 389,403

COMMITMENTS AND CONTINGENCIES (Details)	3 Months Ended		32 Months Ended
COMMITMENTS AND CONTINGENCIES (Details)	Mar. 31, 2019 USD ($) lawsuit	Mar. 31, 2018 USD ($)	Feb. 29, 2016 civil_investigative_demand	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Oct. 31, 2014 facility
Malpractice Insurance [Line Items]
Number of professional liability lawsuits \| lawsuit	78
Cash expenditures for self-insured professional liability costs	$ 1,906,000	$ 1,093,000
Estimated insurance recovery receivables	2,125,000
Litigation contingency	6,400,000			$ 6,400,000	$ 6,400,000
Other Insurance
Liability for workers compensation claims	688,000			618,000
Workers compensation insurance, non current receivable for excess premiums paid	1,458,000			1,258,000
Unfavorable regulatory action \| Potential violations of false claims act
Malpractice Insurance [Line Items]
Number of facilities \| facility						2
Number of civil investigative demands received \| civil_investigative_demand			3
Professional malpractice liability insurance
Malpractice Insurance [Line Items]
Liability for reported and estimated future claims	24,625,000			$ 27,201,000
Prefunded deductible policy
Malpractice Insurance [Line Items]
Insurance policy coverage limits per claim	500,000
Other Insurance
Insurance policy coverage limits per claim	500,000
Professional liability insurance, annual coverage limit per facility	3,000,000
Health insurance, maximum self-insured annual amount per individual	200,000
Liability for reported claims and estimates for incurred but unreported claims	1,444,000
SHC Risk Carriers, Inc \| Professional malpractice liability insurance
Malpractice Insurance [Line Items]
Insurance policy coverage limits per claim	1,000,000
Malpractice insurance annual sublimit per center	3,000,000
Aggregate policy limit	5,000,000
Other Insurance
Insurance policy coverage limits per claim	$ 1,000,000
Scheduled for trial or arbitration over next 12 months
Malpractice Insurance [Line Items]
Number of professional liability lawsuits \| lawsuit	27

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2017	May 31, 2017	Jun. 30, 2016	May 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 140	$ 236
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant of restricted common stock (shares)	151,000	90,000
Restricted Stock \| First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.33%
Restricted Stock \| Second anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.33%
Restricted Stock \| Third anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.33%
2008 Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of quoted market price offering rate	85.00%
Restriction period	2 years
Shares authorized under the plan (shares)					350,000	150,000
2010 Long Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (shares)			680,000	380,000

STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) - Stock Options and Stock Appreciation Rights (SARs) shares in Thousands	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Number of Shares
Outstanding, beginning (shares) \| shares	122
Granted (shares) \| shares	0
Exercised (shares) \| shares	(2)
Expired or cancelled (shares) \| shares	(21)
Outstanding, ending (shares) \| shares	99
Exercisable (shares) \| shares	89
Weighted Average Exercise Price
Outstanding, beginning (dollars per share) \| $ / shares	$ 7.29
Granted (dollars per share) \| $ / shares	0.00
Exercised (dollars per share) \| $ / shares	2.37
Expired or cancelled (dollars per share) \| $ / shares	8.39
Outstanding, ending (dollars per share) \| $ / shares	7.16
Exercisable, weighted average exercise price (dollars per share) \| $ / shares	$ 7.05

STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Restricted Stock Units (RSUs)
Number of Shares
Outstanding, beginning (share) \| shares	120
Granted (shares) \| shares	151
Dividend Equivalents (shares) \| shares	0
Vested (shares) \| shares	(57)
Cancelled (shares) \| shares	0
Outstanding, ending (shares) \| shares	214
Weighted Average Granted Date Fair Value
Outstanding, beginning (dollars per share) \| $ / shares	$ 8.77
Granted (dollars per share) \| $ / shares	3.93
Dividend Equivalents (dollars per share) \| $ / shares	0.00
Vested (dollars per share) \| $ / shares	8.91
Cancelled (dollars per share) \| $ / shares
Outstanding, ending (dollars per share) \| $ / shares	$ 5.31
Employee Stock
Number of Shares
Outstanding, beginning (share) \| shares	43
Granted (shares) \| shares	36
Dividend Equivalents (shares) \| shares	0
Vested (shares) \| shares	(30)
Outstanding, ending (shares) \| shares	49
Weighted Average Granted Date Fair Value
Outstanding, beginning (dollars per share) \| $ / shares	$ 9.26
Granted (dollars per share) \| $ / shares	3.93
Dividend Equivalents (dollars per share) \| $ / shares	0.00
Vested (dollars per share) \| $ / shares	9.76
Outstanding, ending (dollars per share) \| $ / shares	$ 5.05

EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net loss
Loss from continuing operations	$ (3,337)	$ (81)
Loss from discontinued operations, net of income taxes	(9)	(22)
Net loss	$ (3,346)	$ (103)
Per common share – basic
Income (loss) from continuing operations (dollars per share)	$ (0.52)	$ (0.01)
Loss from discontinued operations (dollars per share)	0.00	0.00
Net income (loss) per common share – basic (dollars per share)	(0.52)	(0.01)
Per common share – diluted
Income (loss) from continuing operations (dollars per share)	(0.52)	(0.01)
Loss from discontinued operations (dollars per share)	0.00	0.00
Net income (loss) per common share – diluted (dollars per share)	$ (0.52)	$ (0.01)
Weighted Average Common Shares Outstanding:
Basic (shares)	6,424	6,314
Diluted (shares)	6,424	6,314

EARNINGS PER COMMON SHARE - Narrative (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Earnings Per Share [Abstract]
Antidilutive shares excluded from computation of diluted earnings per share (shares)	99	30

BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) $ in Thousands			12 Months Ended
	Dec. 01, 2018 USD ($)	Oct. 01, 2018 extension center	Dec. 31, 2018 USD ($)	Mar. 31, 2019 center
Business Acquisition [Line Items]
Number of nursing center facilities leased \| center		34		57
Number of skilled nursing centers under lease \| center		23
Operating lease, initial term		12 years
Number of lease extensions allowed \| extension		2
Lease extension period		10 years
Annual lease fixed escalators, percent		2.15%
Kentucky Properties
Business Acquisition [Line Items]
Proceeds from sale of assets \| $	$ 18,700
Carrying value of centers \| $			$ 13,331
Gain on disposition of assets \| $			$ 4,825
Omega Healthcare Investors Inc
Business Acquisition [Line Items]
Number of nursing center facilities leased \| center		11

SUBSEQUENT EVENTS (Details)	Apr. 01, 2019 USD ($) center	Mar. 31, 2019 USD ($)	Dec. 01, 2018 USD ($)	Aug. 01, 2017 USD ($)	Jun. 30, 2017 USD ($)	Oct. 03, 2016 USD ($)	Feb. 26, 2016 USD ($)
Subsequent Event
Subsequent Event [Line Items]
Number of skilled nursing centers participating in QIPP \| center	4
Amended and restated credit agreement \| Amended revolver
Subsequent Event [Line Items]
Borrowing capacity		$ 36,679,000	$ 42,250,000	$ 42,250,000	$ 42,250,000	$ 52,250,000	$ 27,500,000
Amended and restated credit agreement \| Amended revolver \| Subsequent Event
Subsequent Event [Line Items]
Reduction in line of credit capacity	$ 2,000,000
Affiliated Revolving Credit Agreement \| Amended revolver \| Subsequent Event
Subsequent Event [Line Items]
Reduction in line of credit capacity	1,000,000
Borrowing capacity	$ 5,000,000